Concentrix (NASDAQ:CNXC) Sets New 1-Year Low After Earnings Miss

Shares of Concentrix Corporation (NASDAQ:CNXC) reached a new 52-week low during mid-day trading on Tuesday following a weaker than expected earnings announcement. The company traded as low as $24.27 and last traded at $25.4340, with a volume of 2461325 shares. The stock had previously closed at $33.04.

The company reported $2.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.65 by ($0.04). The company had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.49 billion. Concentrix had a negative net margin of 13.35% and a positive return on equity of 17.80%. Concentrix’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.79 EPS.

Concentrix Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 5th. Stockholders of record on Friday, April 24th will be issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 5.8%. The ex-dividend date of this dividend is Friday, April 24th. Concentrix’s payout ratio is presently -6.91%.

Concentrix News Summary

Here are the key news stories impacting Concentrix this week:

• Positive Sentiment: Revenue and business momentum — Q1 revenue rose 5.4% year-over-year and management cites strong enterprise iX Suite wins and continued AI adoption, showing demand for Concentrix’s higher-value solutions. GlobeNewswire: Q1 Results
• Positive Sentiment: Capital return actions — the company declared a $0.36 quarterly dividend (≈5.3% yield) and repurchased ~1M shares in Q1, supporting shareholder income and signaling confidence in the business. Dividend & buyback detail
• Neutral Sentiment: Company guidance maintained full-year revenue and non-GAAP EPS ranges, but Q2 guidance implies modest constant‑currency growth and lower near-term margins — investors are parsing the recovery timeline. See management’s outlook in the release. Guidance
• Neutral Sentiment: Analyst activity is mixed: several firms trimmed price targets but left buy/outperform ratings, creating dispersion in street expectations (see Benzinga summaries). Analyst PT changes
• Negative Sentiment: Margin compression and EPS miss — Q1 non-GAAP operating margin fell ~180–240 bps and GAAP EPS missed estimates; operating income and net income declined sharply (operating income down ~30%, net income down ~69%), which directly pressured the stock. Yahoo: Margin squeeze story
• Negative Sentiment: Cash-flow and leverage concerns — Q1 used cash from operations and adjusted free cash flow was negative; debt-related costs and recent early note redemption added charges. Analysts warn high leverage and negative near‑term FCF increase execution risk. QuiverQuant: cash flow & earnings detail
• Negative Sentiment: Analyst skepticism and downgrades — independent pieces and at least one downgrade argue the transition to AI-driven services is complex and costly, keeping a “hold” view until margins and cash flow recover in H2 2026. That contributed to selling pressure. Seeking Alpha: Downgrade
• Neutral Sentiment: Market data oddities — multiple short‑interest notices in feeds appear inconsistent (zero reported shares), so short‑interest signals are not reliable for today’s move. (Data sources cited in news entries.)

Analyst Ratings Changes

CNXC has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their target price on shares of Concentrix from $80.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday. Barrington Research lowered their price target on Concentrix from $62.00 to $38.00 and set an “outperform” rating on the stock in a report on Wednesday. Wall Street Zen upgraded Concentrix from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Weiss Ratings lowered Concentrix from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, January 29th. Finally, Robert W. Baird reduced their price objective on Concentrix from $52.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Concentrix presently has an average rating of “Hold” and an average price target of $48.50.

Insider Activity

In other Concentrix news, CEO Christopher A. Caldwell bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, January 29th. The stock was bought at an average cost of $37.07 per share, for a total transaction of $37,070.00. Following the completion of the transaction, the chief executive officer owned 362,075 shares of the company’s stock, valued at $13,422,120.25. This represents a 0.28% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada grew its position in shares of Concentrix by 9.5% during the 1st quarter. Royal Bank of Canada now owns 47,501 shares of the company’s stock valued at $2,643,000 after acquiring an additional 4,133 shares during the period. Goldman Sachs Group Inc. raised its holdings in Concentrix by 75.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company’s stock worth $23,552,000 after purchasing an additional 181,546 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Concentrix by 17.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company’s stock valued at $8,152,000 after purchasing an additional 21,746 shares in the last quarter. Focus Partners Wealth bought a new stake in Concentrix during the first quarter valued at about $781,000. Finally, Geneos Wealth Management Inc. grew its holdings in Concentrix by 532.7% during the first quarter. Geneos Wealth Management Inc. now owns 620 shares of the company’s stock valued at $34,000 after purchasing an additional 522 shares during the period. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Concentrix Stock Performance

The company has a debt-to-equity ratio of 1.43, a current ratio of 1.18 and a quick ratio of 1.40. The business has a 50-day simple moving average of $35.01 and a 200 day simple moving average of $40.22. The firm has a market cap of $1.51 billion, a PE ratio of -1.14, a PEG ratio of 0.28 and a beta of 0.50.

About Concentrix

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.